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Abstract
We performed a genome wide analysis of 164 urothelial carcinoma samples and 27 bladder cancer cell lines to identify copy
number changes associated with disease characteristics, and examined the association of amplification events with stage
and grade of disease. Multiplex inversion probe (MIP) analysis, a recently developed genomic technique, was used to study
80 urothelial carcinomas to identify mutations and copy number changes. Selected amplification events were then analyzed
in a validation cohort of 84 bladder cancers by multiplex ligation-dependent probe assay (MLPA). In the MIP analysis, 44
regions of significant copy number change were identified using GISTIC. Nine gene-containing regions of amplification were
selected for validation in the second cohort by MLPA. Amplification events at these 9 genomic regions were found to
correlate strongly with stage, being seen in only 2 of 23 (9%) Ta grade 1 or 1–2 cancers, in contrast to 31 of 61 (51%) Ta
grade 3 and T2 grade 2 cancers, p,0.001. These observations suggest that analysis of genomic amplification of these 9
regions might help distinguish non-invasive from invasive urothelial carcinoma, although further study is required. Both MIP
and MLPA methods perform well on formalin-fixed paraffin-embedded DNA, enhancing their potential clinical use.
Furthermore several of the amplified genes identified here (ERBB2, MDM2, CCND1) are potential therapeutic targets.
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Introduction
Bladder cancer is the fourth most common cancer among men
in the USA, accounting for 73,510 cases and 14,880 deaths in the
US in 2011 [1]. Bladder cancer develops from the transitional cells
of the mucosal urothelium and is found pathologically and
clinically to occur in two mostly separate forms [2]. The first form
is a non muscle-invasive tumor (stages Ta, Tis and T1), which
generally has a good prognosis, but is also characterized by
frequent local recurrences, requiring repeated cystoscopic evalu-
ations. The second form is a solid, non-papillary tumor (stages T2–
T4) that invades into at least the smooth muscle layer (muscularis
propria), and has a high risk for metastasis. Non muscle-invasive
papillary tumors growing in the lumen of the bladder constitute
70–80% of new cases each year, while invasive cases make up the
remaining 20–30% at initial diagnosis [2]. Although the distinc-
tion between papillary and invasive disease is often clear on initial
biopsy, the subsequent clinical behavior of each bladder cancer is
uncertain, and remains a major problem in clinical management
[3]. A variety of histopathologic markers have been assessed and
provide some information on prognosis. However, they do not
provide accurate prediction for individual patients [3]. The
differences in clinical behavior as well as pathologic features
suggest that there are separate oncogenic pathways for non-
muscle-invasive vs. muscle-invasive bladder cancer. The vast
majority of bladder cancers are urothelial carcinoma, and the
same histologic type of cancer can arise throughout the urinary
tract including the renal pelvis and ureters.
In patients with muscle-invasive disease, complete removal of
the bladder with or without cisplatin-based neoadjuvant chemo-
therapy is the most commonly employed treatment approach [2].
Even with radical treatment, approximately 50% of patients
develop metastatic disease, and for such patients no curative
treatment exists. Furthermore, no treatment has been shown to
extend survival in patients with progression following platinum-
based combination chemotherapy. Thus, novel therapeutic and
preventive approaches are needed for this relatively common and
lethal disease.
Genetic studies of bladder cancer have a rich history, including
the identification of the first oncogene, HRAS, in a bladder
carcinoma cell line [4]. Subsequently, TP53 mutations were
identified [5], the CDKN2A gene was shown to be a consistent
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and FGFR3 genes in bladder cancer [7,8], as well as many other
genetic changes. In addition, comparative genomic hybridization
has been used extensively to identify regions of chromosomal gain
and loss in bladder cancer with identification of many consistent
changes of potential importance in tumor development although
the resolution of these technologies was limited [6,9–13].
Here, we report genomic analysis of 164 urothelial carcinoma
samples and 27 bladder cancer cell lines. To assess genomic copy
number changes genome-wide, we performed molecular inversion
probe (MIP) analysis, which works well on formalin-fixed paraffin-
embedded (FFPE) tumor specimens. We identified 44 regions of
copy number change in a discovery cohort of 80 urothelial
carcinoma samples, and then focused on 9 genomic regions
showing significant and relatively common amplification of genes
that may function as ‘driver’ events for urothelial carcinoma
development. We validated these regions in a replication design by
analysis of a set of bladder cancer cell lines, on nearly half of the
original samples, and on a validation cohort of 84 FFPE bladder
cancer samples. We found that genomic copy number changes
were significantly more common in Ta grade 3 and higher stage/
grade tumors than in stage Ta grades 1 and 1–2 tumors. These
observations suggest that analysis of these genomic regions might
be a useful diagnostic tool to determine the invasive potential of
bladder cancer. In addition, the genes in some of these amplified
regions are potential therapeutic targets.
Materials and Methods
Human urothelial carcinoma specimens and cell lines
Urothelial carcinoma specimens that had been formalin fixed
and embedded in paraffin using standard techniques were
obtained from the Pathology archives of the Massachusetts
General Hospital (Table S1). Forty of these samples had portions
that were rapidly frozen at 280uC as well. Written consent was
obtained from each patient for this study on a protocol that was
approved by the hospital’s institutional review board, ‘‘Partners
Human Research Committee’’. Bladder cancer staging was
performed according to the current AJCC guidelines [14]. Grade
was determined according to the 1973 WHO bladder cancer
guidelines [2].
Twenty-four bladder cancer cell lines were obtained from the
stocks of the Translational Urology Research Lab at Massachu-
setts General Hospital, MA. Two other bladder cancer cell lines
were generously provided by Margaret A. Knowles (St James’s
University Hospital, UK) [15], and one was obtained from a
German cancer cell line bank. These 27 bladder cancer cell lines
were maintained in Dulbecco’s Modified Eagle Medium (Cellgro,
Manassas, VA) supplemented with 10% Fetal Bovine Serum and
1% penicillin-streptomycin-amphotericin B (Life Technologies,
Carlsbad, CA), in an incubator at 37uC in 5% CO2. All 27 cell
lines were subject to microsatellite fingerprinting which confirmed
that they were unique.
Anonymized discard normal human blood samples were
obtained from the clinical laboratory at Brigham and Women’s
Hospital on a protocol that was approved by the hospital’s
institutional review board, ‘‘Partners Human Research Commit-
tee’’. These were used to prepare control normal DNA.
DNA extraction
DNA was extracted from formalin-fixed paraffin embedded
(FFPE) samples using the BiOstic FFPE Tissue DNA isolation Kit
(MO BIO Laboratories, Inc., Carlsbad, CA). DNA was extracted
from blood using the QIAGEN DNeasy Blood and Tissue kit.
DNA was extracted from cell lines and frozen cancer specimens
using the Puregene DNA Purification kit following the protocol for
1–2 million cultured cells. DNA concentrations were determined
by nanodrop and confirmed by agarose gel electrophoresis.
Molecular Inversion Probe (MIP) Assay
A molecular inversion probe (MIP) assay examining 330,000
single nucleotide polymorphisms (SNPs) and 412 cancer gene
mutations in 46 cancer-related genes (OncoScan) was performed
with the assistance of Affymetrix in Santa Clara, California [16].
The SNPs had an average intermarker distance of 3 kb for the
150,000 genic probes, and 9 kb for the non-genic probes. The 412
cancer gene mutations are listed in Table S2. The raw data from
this analysis (CEL files) has been put in the GEO archive
(GSE44323).
Biostatistical Software Tools
The raw MIP intensity data provided by Affymetrix was loaded
and analyzed using Nexus Copy Number v6.0 (BioDiscovery Inc.,
El Sequendo, CA). Data was normalized using the SNP-FASST2
segmentation algorithm. Normalized probe intensity and allele
ratio data were visualized in Nexus v6.0. The quality of the copy
number data from each sample was assessed by measuring the
Median of Absolute Pairwise Distribution (MAPD). The absolute
pairwise difference (APD) is calculated as the log2 value of the ratio
of CN intensity values for each adjacent pair of probes, across the
entire set of 330,000 probes.
Normalized copy number data was then segmented using the
GLAD algorithm available in GenePattern 3.3.3 [17]. Recurrent
copy number alterations were identified using Genomic Identifi-
cation of Significant Targets in Cancer (GISTIC) [18], imple-
mented in both GenePattern 3.3.3 and in Nexus v6.0. GISTIC
identifies regions of the genome that are significantly amplified or
deleted across a set of cancer samples. Each amplification or
deletion event is assigned a G-score that considers the amplitude as
well as the frequency of occurrence among the sample set. False
Discovery Rate q-values are then calculated for each region of
gain or loss. Regions with q-values ,0.1 were considered
significant. Genomic coordinates used in the Tables are all from
human build hg18.
Multiplex Ligation-Dependent Probe Amplification
(MLPA)
MLPA probe sets targeting 16 genes in 9 genomic regions were
designed following methods we have used previously [19] (Table
S4). Individual probe oligonucleotides (size range 45–84 nt) were
synthesized by Integrated Device Technology (IDT, Coralville,
IA). MLPA assays were performed on 100–150 ng genomic DNA
samples using the MRC Holland Salsa MLPA EK5 reagent kit
(MRC Holland, Amsterdam, the Netherlands). MLPA products
were separated by capillary electrophoresis on the ABI 3130, and
light intensity reflecting fluorescence was captured according size
of the fragment, in comparison to Rox 500 size standards. Ten to
24 DNA samples were subject to MLPA analysis in each run. For
analysis of control blood DNA and bladder cancer cell line DNAs,
the blood DNA samples were used as controls for normalization,
as described [19]. Because the amplification patterns of FFPE
DNA by MLPA were different from those seen with blood or cell
line DNA, a different method was used for normalization of FFPE
DNA samples. Within each run, peak heights were initially
normalized using all samples analyzed. Samples with no ampli-
fication were then identified and used as normalization controls for
that particular MLPA run. In practice, several FFPE DNA
Genomic Amplification in Urothelial Carcinoma
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repeatedly on different runs and typically served as the controls for
several runs. To determine the reproducibility of the assay,
replicate analyses of samples in different MLPA runs were
compared for each probe value by calculating the coefficient of
variation. The coefficient of variation was calculated as the
standard deviation of a pair of measurements divided by the mean
of those two measurements. A coefficient of variation of ,10%
was considered a robust assay.
Sanger Sequencing
Sanger sequencing was performed on PCR products by
standard methods in the BWH DNA Sequencing Core Facility.
Sequencing traces were viewed and analyzed using FinchTV
v1.4.0.
Statistical methods
The Fisher exact test was used for analysis of categorical data,
and computed in Prism (v4.0a, GraphPad Software, Inc.).
Results
Urothelial carcinoma patient characteristics
One hundred sixty-four urothelial carcinoma specimens pre-
pared in paraffin were used to obtain FFPE DNA for this analysis,
and were divided into two cohorts (Table 1, S1). The discovery
cohort of 80 samples included cystectomy, nephroureterectomy,
and transurethral resection specimens, and had tumor stages
ranging from Ta to T4 (Table 1), but were nearly all T1 or higher
stage to permit robust detection of mutations associated with
invasive urothelial carcinoma. The validation cohort of 84 samples
were obtained exclusively by transurethral resection, were a
sequential series and consisted of tumor stages Ta–T2 (Table 1).
Full clinical and demographic information on these patients and
cancers is given in Table S1.
Molecular Inversion Probe (MIP) genetic mutational
analysis
We used MIP analysis [16], to examine both genomic copy
number and mutation at 412 potential sites in 46 cancer-related
genes (Table S2) on the discovery cohort of 80 urothelial
carcinoma FFPE samples. The wide range of grades and stages
in this cohort were selected by design to permit analysis of the
broad spectrum of urothelial carcinoma. First, we analyzed the
mutations identified by the MIP analysis.
Thirty-two mutations in 7 genes were identified in 28 urothelial
carcinoma samples by Affymetrix criteria (scores$9.0, and ,50)
as being probable mutations in the 80 urothelial carcinoma FFPE
samples. To validate these findings, we performed Sanger
sequencing for each mutation-sample pair, and confirmed 20 of
the 28 mutations that were called in the MIP analysis (Table 2). Of
those that failed to validate, the majority had Affymetrix mutation
scores ,10.0 or .25. Twenty of 22 (91%) mutation calls with
scores between 10.0 and 25 validated by Sanger sequencing.
Molecular Inversion Probe (MIP) genomic copy number
variation analysis
We then focused on analysis of the genomic copy number
information provided by the MIP analysis. Seven (9%) urothelial
carcinoma MIP results were excluded from genomic copy number
analysis due to having a MAPD score .1.5, reflecting a high
variance in probe to probe measurement (see Methods for details).
The median MAPD for the remaining 73 samples was 0.50. Nexus
v6.0 (Bio-Discovery) was used to visualize both copy number and
allele ratio information for the 330,000 SNPs across the genome
(Figure S1).
GISTIC [18] was used to identify regions of significant CN gain
or loss in the 73 urothelial carcinoma samples (Figure 1). Forty-
four chromosomal regions showed a statistically significant CN loss
or gain, with q-value ,0.1 (Table S3). These 44 chromosomal
regions were compared with a large set of similar CN gain and loss
regions available at the tumorscape web-site for other cancers
(http://www.broadinstitute.org/tumorscape), and also examined
using the Integrated Genome Viewer (IGV, see Methods).
Fourteen regions of gain or loss which did not contain protein-
Table 1. Stage and grade information for 164 urothelial
carcinoma samples.
Discovery cohort
stage grade # %
Ta g1,2 3 4%
T1 g2 3 4%
T1 g3 36 49%
T2 g2 1 1%
T2 g3 6 8%
T3 g3 17 23%
T4 g2 2 3%
T4 g3 12 16%
total 80
Validation cohort
stage grade # %
Ta g1 13 15%
Ta g1–2 10 12%
Ta g3 20 24%
T2 g3 41 49%
total 84
Upper, 80 samples in the discovery cohort analyzed by MIP. Bottom, 84 samples
in the validation cohort analyzed by MLPA.
doi:10.1371/journal.pone.0060927.t001
Table 2. Mutations in the discovery cohort of 80 urothelial
carcinoma samples identified by MIP analysis and validated by
Sanger sequencing.
Gene Nucleotide Amino acid #
1 Stages
2
ATM 2572T.C F858L 3 T1, T1, T4
FBXW7 1393C.TR 4 6 5 C 1 T 1
FGFR3 1118A.G Y373C 4 T1, T1, T1, T1
HRAS 34G.A G12S 1 T1
KRAS 35G.A G12D 1 T1
PIK3CA 1624G.A E542K 4 T1, T1, T3, T4
TP53 742C.TR 2 4 8 W 1 T 1
TP53 853G.A E285K 4 T1, T3, T3, T3
TP53 818G.AR 2 7 3 H 1 T 3
1Number of different samples with this mutation.
2Stage of the urothelial carcinoma samples with mutation.
doi:10.1371/journal.pone.0060927.t002
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regions to 16 regions of gain and 14 regions of loss.
We then chose to focus on the 16 regions of amplification since
such regions often contain genes that are ‘drivers’ of cancer
development, and may be amenable to specific therapeutic
targeting. Manual review of high resolution copy number and
allele frequency graphs was performed in both Nexus (Figure S2)
and IGV, and nine regions were identified in which there was high
level amplification with at least 3 of the 73 urothelial carcinoma
samples showing a copy number .5 in the region (Table 3). (Note
that these values are not corrected for stromal cell contamination
in these samples, so that there are likely more samples with true
cancer amplification to .5 copies.) For many of these regions, the
amplification target was known from previous studies in bladder
and other cancers. However, the identity of the gene on
chromosome 1q23.3 was not well-defined from previous work,
and for chromosome 6p22.3, there were two candidate genes,
E2F3 and SOX4. Hence we chose to analyze 16 distinct genes
(Table 4) in a replication study to validate the MIP findings, and
examine the possible association of amplification of these regions
with bladder cancer stage and grade.
Multiplex Ligation-dependent Probe Assay (MLPA) in
bladder cancer cell lines
To replicate these findings, and to generate an assay more easily
applied to routine clinical samples, we generated a set of MLPA
probes for each of the 16 genes in Table 3 (Table S4). The MLPA
assay appeared to work robustly, with the exception of a single
control probe set which was subsequently dropped from consid-
eration, and was applied to a set of control blood DNA samples
and a set of bladder cancer cell lines (Figure S3). Replicate
analyses performed on four blood DNA samples indicated that the
coefficient of variation for copy number determined by MLPA
analysis was a median of 3.64% and a mean of 4.40%, indicating a
relatively low level of variation in this assay. Replicate analyses of
copy number performed on 25 bladder cancer cell line DNA
preparations indicated that the coefficient of variation was a
median of 6.57% and a mean of 7.77% (two samples could not be
replicated due to insufficient DNA). This is still a relatively low
level of variation, but is higher than blood DNA samples, likely
due to the presence of amplified regions in many of the bladder
cancer cell lines, which diminishes the size of non-amplified
products, increasing the variance in duplicate measurements.
Figure 1. GISTIC plot of genomic regions with CN gain or loss from the MIP analysis on 73 urothelial carcinoma specimens. The 21
autosomes are shown on the y axis, and q values indicating statistical significance from the GISTIC analysis are plotted on the x axis for regions of
copy number gain (red at left) and loss (blue at right).
doi:10.1371/journal.pone.0060927.g001
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PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60927Eleven of 27 (41%) bladder cancer cell lines analyzed by the
MLPA assay had amplification of one or more of the 16 genes
assayed (Table 5), while the remainder had no amplification
among the tested genes, considering amplification to be 4 or more
copies. Six (22%) cell lines showed amplification of CCND1, while
5 each showed amplification of some or all of the genes on 1q23.3
and of E2F3-SOX4. No cell line had amplification of POLB or
ERBB2. These findings validate the original MIP analysis as 7 of
the 9 genomic regions of amplification seen by MIP analysis were
also seen in these bladder cancer cell lines.
MLPA validation of MIP analysis
To further validate the copy number findings made in the MIP
analysis, we performed MLPA analysis of DNA prepared from
parallel fresh frozen samples from 39 of the cancers analyzed in
the first cohort of 80 FFPE samples. We found that 343 of 351
(98%) of the chromosomal regions analyzed on the paired samples
by the two methods showed concordance in detection of
amplification or lack of amplification, assessed as CN . 4.
Furthermore of the 27 chromosomal regions of amplification
detected by either MIP or MLPA analysis in individual samples,
19 (70%) showed concordance by the two methods of analysis.
Concordant results were seen for amplification in 8 of the 9
genomic regions analyzed for one or more cancers. We suspect
that the lack of concordance seen for some samples may reflect
tumor heterogeneity with significant differences in gene amplifi-
cation events seen in different samples of the same cancer, or
possibly differences in tumor content in the two samples. Overall,
we take these findings as strong validation of the MIP analysis
method.
MLPA analysis of the validation cohort and comparison
with stage
We then performed a replication analysis assessing amplification
of these 9 genomic regions and 16 genes on the validation cohort
of 84 FFPE bladder cancer DNA samples. Furthermore, we
examined the possibility that genomic amplification of these
regions would be associated with stage of disease, and thus might
provide a potential prognostic measure for clinical use. Since most
clinical bladder cancer specimens on which initial treatment
decisions are based are derived from transurethral resection, we
analyzed FFPE samples obtained only by that means, and that
ranged in stage from Ta grade 1 through T2 grade 3.
To demonstrate the reproducibility of the MLPA assay on FFPE
DNA samples, replicate analyses were performed on 26 of the 84
FFPE samples, all of those for which DNA was available. On these
samples the coefficient of variation for replicate analyses had a
median of 5.66% and an average of 6.75%, indicating that the
MLPA assay was reproducible and robust.
Considering amplification to be 4 or more copies, 33 of 84
(39%) samples analyzed showed amplification of one or more
genomic regions (Table 6). Similar to the findings with the bladder
cancer cell lines, CCND1, the chromosome 1q23.3 region, and
E2F3-SOX4 were the most commonly amplified, seen in 11
(13%), 8 (10%), and 12 (14%) samples, respectively.
The frequency of any amplification event was strongly
correlated with tumor stage and grade (Table 7). Amplification
events were seen in only 2 of 23 (9%) Ta grade 1 or 1–2 cancers.
In contrast, amplifications were seen in 11 of 20 (55%) Ta grade 3
cancers, and in 20 of 41 (49%) T2 grade 2 cancers. Comparison of
the frequency of amplification among these three groups is highly
significant with p=0.0020 and 0.0011, comparing the first group
with each of the second two groups (Fisher’s exact test). SOX4 was
the only individual marker which showed amplification at a
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PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e60927significantly higher rate in Ta grade 3+T2 grade 2 cancers (11 of
61) than in Ta grade 1 or 1–2 cancers (0 of 23, p=0.03).
Examination of the frequency of amplification of these 9 genomic
regions in the discovery cohort of 73 samples analyzed by MIP
assay showed a similar trend, but the results were not statistically
significant due to the small number of Ta tumors in that cohort.
None of 3 Ta grade 1 or 2 samples showed amplification, and 31
(44%) of 70 T1–T4 samples showed amplification of one or more
of the 9 genomic regions. Since the low frequency of copy number
variation in the Ta grade 1 and 1–2 samples might be explained
by presence of normal tissue rather than bladder cancer in those
specimens, we examined them for mutations in FGFR3. Ten of 11
samples examined (4 grade 1 and 7 grade 1–2) had mutations in
FGFR3: 1 had R248C, 8 had S249C, and 1 had Y373C,
consistent with previous studies of early stage bladder cancer
[20,21].
Discussion
In this study, we used an innovative methodology, MIP analysis,
to examine both a set of 412 mutations and to perform copy
number analysis across the genome using 330,000 SNP probes.
The MIP procedure enables analysis of FFPE DNA, the most
commonly available clinical material. Most mutations identified
here were in the 12 most commonly mutated genes reported by
the Catalogue of Somatic Mutations in Cancer (COSMIC) in
bladder cancer [22]. However, we also identified mutations in two
other genes not reported in COSMIC for bladder cancer, ATM
and FBXW7. Relatively few mutations in FGFR3 were seen in this
cohort, four Y373C (5%), likely due to the inclusion of only three
Ta samples, two of which arose in the renal pelvis. MIP screening
for mutation and copy number change has recently been reported
for multiple other cancer types [23–27].
We choose to focus on copy number amplifications, and
identified 9 genomic regions of common amplification in an initial
cohort of 80 urothelial carcinoma specimens, of which 73 gave
reliable copy number information by MIP analysis. We then
generated a set of MLPA probes to interrogate those nine regions
in a validation cohort of 84 samples. We demonstrated that the
performance of the MLPA analysis was robust on control blood
DNAs, bladder cancer cell line DNAs, and frozen DNA samples
from a subset (39) of the cancers initially evaluated by MIP analysis
of FFPE DNA. We then performed the MLPA analysis on a
separate validation cohort of 84 bladder cancer FFPE DNA
samples. In the validation cohort, we found that all genomic
regions showed evidence of amplification in two or more samples,
with the highest levels of amplification seen for CCND1 and
MDM2 (Table 6). The regions with the most frequent amplifica-
tion were chromosome 1q23.3, E2F3-SOX4, and CCND1
(Table 6). Amplification was seen significantly more frequently
in advanced stage tumors (Ta grade 3, or higher stage) than in
early stage tumors (Ta grade 1 or 1–2).
Many previous studies have analyzed genomic copy number
changes in bladder cancer using comparative genomic hybridiza-
tion (CGH) or array CGH [3,9,10,12,13,28–40]. All of the 9
genomic regions with amplification identified in our MIP analysis
that contained genes, were highly statistically significant, and were
identified in multiple samples, had been identified in these
previous studies. However, MYCL1 and POLB have been
identified previously in only one or two studies [9–11,13,38,41].
In our validation cohort, we identified MYCL1 and POLB
amplification in 3 and 4 samples, respectively. The validation we
performed using MLPA analysis of the original MIP samples, and
the consistency of these findings strongly support both the value of
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PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e60927MIP analysis as a technology for copy number alteration
detection, and provide further validation for the importance of
these amplification events in bladder cancer development.
Many previous studies have also found that there is a major
difference in genomic events seen in superficial papillary bladder
cancer (Ta), in comparison to more advanced stages of disease.
Non-invasive Ta papillary tumors commonly have activating
mutations in FGFR3 (as seen here), or mutation in one of the RAS
genes (mutually exclusive with FGFR3 mutation), and loss of one
chromosome 9 [41]. However, few other genomic alterations have
been seen by past CGH, array-CGH, or SNP analyses [11,13,41].
Amplification events are generally rare [41], but have recently
been identified at a low level in Ta disease [36]. In contrast, many
genetic events have been identified in muscle-invasive bladder
cancer, including common deletion and mutations in TSC1,
PTEN, RB1, and particularly TP53. In addition, recent studies
have emphasized the common involvement of the PI3K–mTOR
pathway in this disease [15,42], and common mutation in
chromatin remodeling genes in invasive bladder cancer [43].
Further investigation of FBXW7 in bladder cancer pathogenesis
given its reported involvement in this pathway [44] is of interest.
In aggregate, these observations suggest that a relatively simple
assay for amplification of these 9 genomic regions might provide
useful clinical information. This might be achieved by the MLPA
technique as shown here which can be performed on FFPE tissues.
There are also other efficient approaches that could be used for
this purpose, including digital droplet PCR [45]. However, prior
to clinical use of this analysis, a similar copy number analysis will
need to be performed on a large set of stage 1 bladder cancer
patients in whom there is good follow-up data to assess the
potential prognostic value of this assay.
Most previous genomic studies on bladder cancer have used
fresh frozen tissue obtained by cystectomy. In contrast, FFPE
samples are the common pathologic resource available in routine
clinical practice at the time of critical decision-making. Therefore,
molecular tests that can use FFPE DNA are essential. In our study,
we demonstrated that MIP technology can be used to study
routine FFPE cancer specimens, providing a great deal of
mutational and copy number information. We also demonstrated
that the simpler MLPA technique also works well on FFPE DNA.
Several of the genes included in our MLPA assay represent
potential druggable targets. CCND1 amplified bladder cancers
may be sensitive to CDK4 inhibitors [46]; ERBB2 amplified
tumors may be sensitive to lapatinib, trastuzumab, or T-DM1
[47]; and MDM2 inhibitors are in current clinical development
[48]. The specific clinical importance of each of these alterations
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Table 7. Summary of MLPA findings in FFPE bladder cancer
samples according to stage.
total # any CN$4.0 %
group 1 Ta grade 1 13 0 0%
Ta grade1–2 10 2 20%
group 2 Ta grade 3 20 11 55%
group 3 T2 grade 3 41 20 49%
total 84 33 39%
Groups 1, 2, and 3 have a statistically significant difference in the frequency of
any amplification event, with p=0.0020 comparing groups 1 and 2, and
p=0.0011 comparing groups 1 and 3. P is not significant comparing group 2
with group 3. Fisher exact test.
doi:10.1371/journal.pone.0060927.t007
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PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e60927in bladder cancer has yet to be determined, but clearly there is
promise. Hence detection of amplification in these genes in
bladder cancer might also lead to targeted therapy.
Supporting Information
Figure S1 Visualization of copy number and allele
specific intensity for 330,000 SNPs using Nexus v6.0. In
each quadrant of this figure there are graphs of the intensity of
signal for each pair of SNP probes (upper), and each allele (lower).
Graphs are shown for four samples: a normal bladder FFPE
sample in the upper left; and three different urothelial cancer
FFPE samples in the other 3 quadrants. Note that the copy
number graph has been normalized such that a y axis value of 0
corresponds to the normal two copies, and other values reflect
either copy number loss (negative) or gain (positive). The allele
fraction graph shows the relative signal intensity for each of the
two alleles, and SNPs for which one allele has no signal have been
screened out. The normal control bladder sample is diploid across
the entire genome, and has a uniform 50% intensity value for all
heterozygous SNPs. The urothelial carcinoma specimens show a
variety of copy number changes and allele ratio distortions. Note
region of major amplification seen on chromosomes 16p, 18p, and
21 in sample 30 at lower left, indicated by red stars.
(TIF)
Figure S2 Amplified genomic regions in urothelial
carcinoma visualized using Nexus v6.0. In each quadrant
of this figure, graphs are shown for four different urothelial
carcinoma samples and for three different genomic regions. In
each quadrant, chromosome cytoband is shown at top, followed by
a graph of the total SNP probe intensity, then a graph of the allele
specific SNP probe intensity, and then information about the nt
start and end position of the amplification, the number of SNP
probes in the amplification, and the probe mean and median
signals within the amplification. Each dot represents a different
SNP analyzed.
(TIF)
Figure S3 MLPA analysis on control, bladder cancer cell
line, and urothelial carcinoma DNA samples. Elution
intensity curves are shown for MLPA products analyzed on the
ABI 3130. Y axis is light intensity in arbitrary units, reflecting
fluorescence; X axis is the size of the DNA fragment being eluted
from the capillary. Boxed labels indicate the gene or genomic locus
for each elution peak. Note the relatively even size of all probe
peaks in the control sample. Note that there is selective increase in
the relative signals for the SOX4 and E2F3 probes in the bladder
cancer cell line sample. Note that other regions of relative increase
are seen in the lower two urothelial carcinoma samples, E2F3 and
POLB, respectively.
(TIF)
Table S1 List of all urothelial carcinoma samples
analyzed.
(XLS)
Table S2 List of all mutations assessed in the MIP
analysis.
(XLSX)
Table S3 Chromosomal regions identified by GISTIC
analysis of MIP data with significant CN gains or losses,
with q,0.1. The chromosomal region, CN change, q value, and
G-score (GISTIC) are shown for each region.
(XLS)
Table S4 MLPA probe sequences used in this study.
(XLSX)
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